The VR-36© and VR-12© are generic instruments to measure health related quality of life. The VR-6D© is a utility metric derived from the VR-12© useful in cost-effectiveness analyses. There are more than 5 million administrations globally.
The VR-36©, VR-12© and VR-6D© questionnaires, scoring algorithms and imputation programs are all in the public domain and available for use on special request from the developers.
Request permission to use the VR-36©, VR-12© or VR-6d© documentation and scoring algorithms.
The VR-36©, VR-12© and VR-6D© were developed with the support and endorsement of the Department of Veterans Affairs and the Centers for Medicare and Medicaid Services.
The computer programs to create VR scales and PCS/MCS summaries are copyright (all rights reserved) by the Trustees of Boston University to ensure the integrity of the assessments.
In August 2017, the New England Journal of Medicine published an article that examined whether the results from the Systolic Blood Pressure Intervention Trial (SPRINT) affected patient-reported outcome measures (assessed using the VR-12). The study found that patient-reported outcomes were similar across the intensive treatment group (targeted systolic blood pressure of less than 120 mmHg) and standard treatment group (targeted systolic blood pressure of less than 140 mmHg).
Full article: http://www.nejm.org/doi/full/10.1056/NEJMoa1611179